The board of directors of Charmacy Pharmaceutical Co., Ltd. informed the shareholders of the company and potential investors that, based on a preliminary review of the management accounts of the Group for the year ended 31 December 2016 and the information currently available to the Board, the Group is expected to record a growth of not less than 110% in the Group's profit attributable to the owners of the company for the year ended 31 December 2016 as compared with that of the year ended 31 December 2015 that is audited profit attributable to the owners of the company for the year ended 31 December 2015 amounted to approximately RMB 26.36 million. The anticipated substantial increase is mainly due to (i) increases in sales of products and gross profit of the Group; and (ii) there is no listing expense for the year ended 31 December 2016 as compared with that of the year ended 31 December 2015.